Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANALYSIS: Healthcare IT lifts September’s VC takings

This article was originally published in Clinica

Executive Summary

September brought a new low in the number of medtech venture financing deals, with only 16 transactions of $1m or over recorded. This is the smallest monthly deal volume this year to date, and is a significant 20% drop from August, which only had 20 transactions (www.clinica.co.uk, 10 September 2013). However, dollar-wise, September beat August by raking in over $209m, not including the one transaction that did not disclose the sum raised. This was down to the absence of big-buck deals in August, where the total VC dollars raised slipped just past $179m, while September had a whopping $70m Series D transaction to hike up the total deal value that month (see Fig 1). Excluding this transaction, the total deal value for September would have been well below that of August at $139m, as there was even a significant decrease in the number of small, below-$10m financings.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT100925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel